Clinical trials: AD - Alzheimer's Disease
Alzheimer's Disease With Vascular Pathology
A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology
This study is being conducted to test the safety, tolerability, and pharmacokinetics of the investigational drug CY6463 compared with placebo in individuals who are aged 60 years or older and have Alzheimer's disease (AD) along…
- Trial name
- NCT04798989
- Testing
- CY6463
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Tisento Therapeutics
Alzheimer's Disease
Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol
Open-label treatment with MPC-7869 for participants in a previous randomized study.
- Trial name
- NCT00380276
- Testing
- MPC-7869
- Where
- 90 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Myrexis Inc.
Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo…
- Trial name
- HOPE4MCI (NCT03486938)
- Testing
- AGB101 220 mg tablet
- Where
- 24 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- AgeneBio
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in PACC5 between baseline and +12 month follow up across all four Arms, as…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-FUTURE (NCT04846426)
- Where
- 4 sites in United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer Disease (AD)
A Study Evaluating the Efficiency and Safety for the VGuard Device in Alzheimer's Disease.
The project will allow the assessment of the safety and clinical effectiveness of the device for the treatment of cognitive impairment at Alzheimer\'s diease.
- Trial name
- CogniGuard (NCT06620640)
- Testing
- Intervention will most probably modify activity of neuron networks in specific brain areas responsible for cognitive functions, especially memory consolidation.
- Where
- Poland
- Volunteers
- 105 people
- Sponsor
- Neuromedical Sp. z o.o.
Alzheimer Disease
Vielight Neuro RX Gamma - Feasibility Pilot
This study tests the effects of the Neuro RX Gamma synchronous and asynchronous devices on the cognitive and behavioral functioning of subjects with moderate-to-severe Alzheimer's Disease.
- Trial name
- NCT03328195
- Testing
- Neuro RX Gamma synchronous, Neuro RX Gamma asynchronous
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Vielight Inc.
Dementia, Alzheimer's Disease
Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia
The purpose of this trial is to test the safety \& tolerability of intramuscular aripiprazole in acutely agitated patients diagnosed with Dementia.
- Trial name
- NCT00095719
- Testing
- Aripiprazole
- Where
- 14 sites in United States
- Volunteers
- 125 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease
Safety, Tolerability, and Pharmacokinetics Study of NDX-1017
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of NDX-1017 in healthy young and elderly subjects…
- Trial name
- NCT03298672
- Testing
- NDX-1017
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- LeonaBio
Alzheimer Disease
A Study of AMDX-2011P in Participants With Alzheimer's Disease
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
- Trial name
- NCT06514001
- Testing
- AMDX-2011P
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Amydis Inc.
Mild to Moderate Alzheimer's Disease
4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease
The primary purpose of the study is to determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil for 4 weeks in patients with mild to moderate Alzheimer's disease.
- Trial name
- ROBIN (NCT01039701)
- Testing
- AZD1446
- Where
- 12 sites in Czechia, Hungary and 1 more
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Alzheimer Disease
Effect of CT1812 Treatment on Brain Synaptic Density
Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.
- Trial name
- NCT03493282
- Testing
- Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Cognition Therapeutics
Alzheimers Disease
A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
[F-18]T808 is being developed as a diagnostic radiopharmaceutical for PET imaging of the human brain.
- Trial name
- T808 (NCT01723488)
- Testing
- [F18] T808
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
Subjects will be adults aged 50 to 85 years who have subjective memory complaints and mild cognitive impairment or mild dementia due to Alzheimer's disease (AD).
- Trial name
- NCT01600859
- Testing
- E2609
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
Purpose of the study is to determine whether multiple dose administration of PF-04360365 is safe and well tolerated in patient with mild to moderate Alzheimer's disease.
- Trial name
- NCT00722046
- Testing
- PF-04360365 0.1 mg/kg, PF-04360365 0.5 mg/kg, PF-04360365 1 mg/kg
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 198 people
- Sponsor
- Pfizer
Agitation,Psychomotor, Disruptive Behavior
A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.
This double-blind, placebo-controlled study is designed to assess the effectiveness of, MediCane's medical cannabis oil extracted from MediCane's proprietary strain into GMP-grade olive oil, as an add-on therapy to standard of…
- Conditions
- Agitation,Psychomotor, Disruptive Behavior, Dementia, Alzheimer Disease
- Trial name
- NCT06217146
- Testing
- Medical Cannabis
- Where
- 3 sites in Israel
- Volunteers
- 24 people
- Sponsor
- M. H MediCane Ltd.
Alzheimer Disease
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
- Trial name
- NCT06995573
- Testing
- NSC001
- Where
- 10 sites in Austria, Germany
- Volunteers
- 90 people
- Sponsor
- NSC-Therapeutics
Alzheimer's Disease
Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease
This proof-of-concept study will assess safety, tolerance, and efficacy of NanoLithium® NP03 in patients with mild-to-severe Alzheimer's Disease (AD).
- Trial name
- NanoLi®_AD (NCT05423522)
- Testing
- NanoLithium® NP03
- Where
- 8 sites in France
- Volunteers
- 72 people
- Sponsor
- Medesis Pharma SA
Mild Cognitive Impairment, Alzheimer's Disease
Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements
In a retrospective analysis of data from 1100 patients, disease-delaying effects of Cerefolin®/CerefolinNAC® were examined in terms of cognition.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease Related Disorders
- Trial name
- NCT01745198
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Pamlab, Inc.
Alzheimer's Disease
A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)
A study to assess the effect of heat application on the delivery profile of Corplex™ Donepezil Transdermal Delivery System (TDS)
- Trial name
- NCT03438604
- Testing
- Donepezil TDS
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Corium, Inc.
Neurodegenerative Diseases, Alzheimer's Disease
A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease
SNP318 is developed to treat neurodegenerative diseases including Alzheimer's disease. In the current phase 1 study, the IP is tested in healthy volunteers, and the purpose is to investigate the safety, tolerability, and PK of…
- Trial name
- NCT05792163
- Testing
- SNP318 (A)
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- SciNeuro
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.